Rituximab News and Research

RSS
Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.
Rituximab outperforms fingolimod after natalizumab switch

Rituximab outperforms fingolimod after natalizumab switch

Rituximab drug more effective than fingolimod for patients with highly active multiple sclerosis

Rituximab drug more effective than fingolimod for patients with highly active multiple sclerosis

Rituximab shows second-line promise in autoimmune limbic encephalitis

Rituximab shows second-line promise in autoimmune limbic encephalitis

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

Lenalidomide trials show potential for expanding lymphoma, leukaemia indications

Lenalidomide trials show potential for expanding lymphoma, leukaemia indications

Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma

Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

New approaches to treating leukemia, lymphoma and myeloma

New approaches to treating leukemia, lymphoma and myeloma

Potential for chemotherapy-free standard of care in advanced mantle cell lymphoma

Potential for chemotherapy-free standard of care in advanced mantle cell lymphoma

Health experts urge lawmakers, regulators to close loopholes in Orphan Drug Act

Health experts urge lawmakers, regulators to close loopholes in Orphan Drug Act

Drug combination produces long-term responses in patients with mantle cell lymphoma

Drug combination produces long-term responses in patients with mantle cell lymphoma

New campaign raises awareness of City of Hope's life-saving mission and impact

New campaign raises awareness of City of Hope's life-saving mission and impact

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Hetero Group launches biosimilar 'Rituximab' under brand name MABALL in India

Hetero Group launches biosimilar 'Rituximab' under brand name MABALL in India

Steroid-refractory chronic GVHD trial results ‘overestimate’ treatment efficacy

Steroid-refractory chronic GVHD trial results ‘overestimate’ treatment efficacy

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

New treatment option available for CLL patients in Manitoba and Saskatchewan

New treatment option available for CLL patients in Manitoba and Saskatchewan

Autoantibodies play major role in IPF patients with acute exacerbations

Autoantibodies play major role in IPF patients with acute exacerbations

People with rheumatoid arthritis less likely to benefit from hepatitis B vaccine

People with rheumatoid arthritis less likely to benefit from hepatitis B vaccine

Ibrutinib shows promise in CLL/SLL

Ibrutinib shows promise in CLL/SLL